{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:07:19Z","timestamp":1778947639522,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2023QD12"],"award-info":[{"award-number":["2023QD12"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008856","name":"Department of Health of Zhejiang Province","doi-asserted-by":"publisher","award":["2025KY692"],"award-info":[{"award-number":["2025KY692"]}],"id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lfs.2026.124355","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:14:08Z","timestamp":1774628048000},"page":"124355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MAPK1 phosphorylates CCNB1 at Ser128 to drive mitotic progression and cell proliferation in triple-negative breast cancer"],"prefix":"10.1016","volume":"394","author":[{"given":"Beinan","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiren","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongde","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lfs.2026.124355_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"10286","key":"10.1016\/j.lfs.2026.124355_bb0010","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lfs.2026.124355_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast Cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2026.124355_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.lfs.2026.124355_bb0025","first-page":"221","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"2","key":"10.1016\/j.lfs.2026.124355_bb0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10265","key":"10.1016\/j.lfs.2026.124355_bb0035","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lfs.2026.124355_bb0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2026.124355_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceb.2025.102526","article-title":"ERK1\/2-MAPK signaling: metabolic, organellar, and cytoskeletal interactions","volume":"95","author":"Martin-Vega","year":"2025","journal-title":"Curr. Opin. Cell Biol."},{"issue":"6","key":"10.1016\/j.lfs.2026.124355_bb0050","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1634\/theoncologist.2011-0377","article-title":"High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients","volume":"17","author":"Bartholomeusz","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.lfs.2026.124355_bb0055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.molmed.2025.08.001","article-title":"Targeting pathological ERK1\/2 signaling in cancer and beyond","volume":"32","author":"Schanbacher","year":"2025","journal-title":"Trends Mol. Med."},{"issue":"14","key":"10.1016\/j.lfs.2026.124355_bb0060","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","article-title":"In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models","volume":"15","author":"Hoeflich","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.lfs.2026.124355_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215306","article-title":"The predictive and prognostic role of RAS-RAF-MEK-ERK pathway alterations in breast Cancer: revision of the literature and comparison with the analysis of Cancer genomic datasets","volume":"14","author":"Rocca","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.lfs.2026.124355_bb0070","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.leu.2402945","article-title":"Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.lfs.2026.124355_bb0075","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.bjc.6602051","article-title":"Dual blockade of EGFR and ERK1\/2 phosphorylation potentiates growth inhibition of breast cancer cells","volume":"91","author":"Lev","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.lfs.2026.124355_bb0080","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.annonc.2021.01.065","article-title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","volume":"32","author":"Brufsky","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2026.124355_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-024-07551-z","article-title":"Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795\/uprosertib in patients with metastatic triple negative breast cancer","volume":"210","author":"Prasath","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.lfs.2026.124355_bb0090","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1038\/s41598-020-65250-3","article-title":"Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer","volume":"10","author":"Gagliardi","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.lfs.2026.124355_bb0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.lfs.2026.124355_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061205","article-title":"Dual inhibition of AKT and MEK pathways potentiates the anti-Cancer effect of Gefitinib in triple-negative breast Cancer cells","volume":"13","author":"You","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.lfs.2026.124355_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/jbiol38","article-title":"ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially","volume":"5","author":"Vantaggiato","year":"2006","journal-title":"J. Biol."},{"issue":"10","key":"10.1016\/j.lfs.2026.124355_bb0110","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sj.embor.embor939","article-title":"An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development","volume":"4","author":"Saba-El-Leil","year":"2003","journal-title":"EMBO Rep."},{"issue":"6","key":"10.1016\/j.lfs.2026.124355_bb0115","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41388-021-02142-4","article-title":"NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1\/2-mediated Fbxw7 phosphorylation","volume":"41","author":"Shu","year":"2022","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.lfs.2026.124355_bb0120","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1128\/MCB.21.16.5500-5511.2001","article-title":"Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2","volume":"21","author":"Knauf","year":"2001","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.lfs.2026.124355_bb0125","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.1038\/s41467-023-44089-y","article-title":"ERK2-topoisomerase II regulatory axis is important for gene activation in immediate early genes","volume":"14","author":"Bunch","year":"2023","journal-title":"Nat. Commun."},{"issue":"43","key":"10.1016\/j.lfs.2026.124355_bb0130","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Luciano","year":"2003","journal-title":"Oncogene"},{"issue":"34","key":"10.1016\/j.lfs.2026.124355_bb0135","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1038\/s41388-019-0865-8","article-title":"SOX7 regulates MAPK\/ERK-BIM mediated apoptosis in cancer cells","volume":"38","author":"Sun","year":"2019","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.lfs.2026.124355_bb0140","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1111\/febs.15828","article-title":"FBXW8 regulates G1 and S phases of cell cycle progression by restricting \u03b2-TrCP1 function","volume":"288","author":"Islam","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.lfs.2026.124355_bb0145","article-title":"Large-scale discovery of ERK2 substrates identifies ERK-mediated transcriptional regulation by ETV3","volume":"4(196):rs11","author":"Carlson","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.lfs.2026.124355_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2022.104543","article-title":"Identification and validation of new ERK substrates by phosphoproteomic technologies including Phos-tag SDS-PAGE","volume":"258","author":"Yoshikawa","year":"2022","journal-title":"J. Proteome"},{"key":"10.1016\/j.lfs.2026.124355_bb0155","first-page":"4","article-title":"Myths in rheumatology","volume":"4(2):suppl","author":"McDonald-Scott","year":"1989","journal-title":"Nurs. RSA"},{"issue":"45","key":"10.1016\/j.lfs.2026.124355_bb0160","doi-asserted-by":"crossref","first-page":"37997","DOI":"10.1074\/jbc.M112.373464","article-title":"Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2\/M","volume":"287","author":"Illert","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"54","key":"10.1016\/j.lfs.2026.124355_bb0165","doi-asserted-by":"crossref","first-page":"8282","DOI":"10.1038\/sj.onc.1206011","article-title":"Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1","volume":"21","author":"Yuan","year":"2002","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.lfs.2026.124355_bb0170","first-page":"3860","article-title":"Phosphorylation of Xenopus cyclins B1 and B2 is not required for cell cycle transitions","volume":"11","author":"Izumi","year":"1991","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.lfs.2026.124355_bb0175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol Biomed."},{"issue":"11","key":"10.1016\/j.lfs.2026.124355_bb0180","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.tips.2019.09.005","article-title":"Comprehensive analysis of ERK1\/2 substrates for potential combination immunotherapies","volume":"40","author":"Yang","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"46","key":"10.1016\/j.lfs.2026.124355_bb0185","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035802","article-title":"Role of CCNB1, CENPF, and neutrophils in lung cancer diagnosis and prognosis","volume":"102","author":"Tan","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.lfs.2026.124355_bb0190","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.mehy.2014.06.013","article-title":"CCNB1 is a prognostic biomarker for ER+ breast cancer","volume":"83","author":"Ding","year":"2014","journal-title":"Med. Hypotheses"},{"issue":"1","key":"10.1016\/j.lfs.2026.124355_bb0195","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13046-025-03463-y","article-title":"SNRPB\/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming","volume":"44","author":"Jin","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lfs.2026.124355_bb0200","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ctrv.2013.03.009","article-title":"Targeting the PI3K\/AKT\/mTOR and Raf\/MEK\/ERK pathways in the treatment of breast cancer","volume":"39","author":"Saini","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"32","key":"10.1016\/j.lfs.2026.124355_bb0205","article-title":"The role of targeting CDK4\/6 in cancer immunotherapy.Holist. Integ. Oncol","volume":"3","author":"Sun","year":"2024"},{"issue":"8031","key":"10.1016\/j.lfs.2026.124355_bb0210","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41586-024-07888-x","article-title":"CDK5-cyclin B1 regulates mitotic fidelity","volume":"633","author":"Zheng","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2026.124355_bb0215","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/ncomms7769","article-title":"CDK1 structures reveal conserved and unique features of the essential cell cycle CDK","volume":"6","author":"Brown","year":"2015","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.lfs.2026.124355_bb0220","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0955-0674(00)00149-6","article-title":"Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C","volume":"12","author":"Takizawa","year":"2000","journal-title":"Curr. Opin. Cell Biol."},{"issue":"2","key":"10.1016\/j.lfs.2026.124355_bb0225","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1083\/jcb.200909144","article-title":"Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis","volume":"189","author":"Gavet","year":"2010","journal-title":"J. Cell Biol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526001645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526001645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:10:30Z","timestamp":1778944230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526001645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"alternative-id":["S0024320526001645"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124355","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MAPK1 phosphorylates CCNB1 at Ser128 to drive mitotic progression and cell proliferation in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"124355"}}